Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CASP3 | P42574 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557820 | 1.00 | KMT2A (0.58) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL556887 | 1.00 | KMT2A (0.58) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL8882675 | 0.91 | KMT2A (0.66) | KMT2ACASP3PTPN1 | |
| SCHEMBL12291725 | 0.89 | KMT2A (0.52) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL30670318 | 0.87 | CASP3 (0.64) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29400419 | 0.87 | CASP3 (0.64) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL7391100 | 0.87 | CASP3 (0.64) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL3195920 | 0.87 | CASP3 (0.64) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29511466 | 0.87 | CASP3 (0.64) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL119717 | 0.87 | CASP3 (0.64) | KMT2ACASP3MDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841257-B2 | Inhibitors of STAT3 and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | KMT2A 2506/4885CASP3 1071/4885PTPN1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.